2002, Biosimilars and Communication

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2002

Biosimilars

Communication

A history of Johnson & Johnson

pharmaphorum

FEBRUARY 26, 2021

The company has also faced claims that it did not adequately communicate the risks of its opioid painkillers in its marketing, contributing to the US’ ‘opioid epidemic’, and that its talc products could contain small amounts of asbestos and lead to cancer. Weldon became the Chairman and CEO of J&J in 2002.

Vaccines

Three strategies for managing loss of exclusivity successfully

pharmaphorum

FEBRUARY 18, 2021

6 The stakes were extremely high, with annual costs of insulin reaching $736 per patient in 2013, up threefold since 2002. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. RESULT: As of 2002, 40% of PRILOSEC patients had switched to NEXIUM, which notched up sales of $3.9 billion in 2004.14

Prescription Filling

Prescription Filling Drug Pricing Biosimilars Compounding

Pharmacist Digest

A history of Johnson & Johnson

Three strategies for managing loss of exclusivity successfully

Stay Connected